<h4>Background and purpose</h4>Empagliflozin (EMP) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the management of type 2 diabetes mellitus. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.